Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 11
1988 43
1989 88
1990 174
1991 322
1992 534
1993 657
1994 675
1995 792
1996 762
1997 693
1998 736
1999 688
2000 761
2001 798
2002 782
2003 860
2004 893
2005 903
2006 855
2007 922
2008 788
2009 853
2010 931
2011 1051
2012 962
2013 970
2014 913
2015 796
2016 531
2017 398
2018 274
2019 110
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

20,238 results
Results by year
Filters applied: . Clear all
Page 1
The use of interferon alpha in Behçet disease: review of the literature.
Kötter I, et al. Semin Arthritis Rheum 2004 - Review. PMID 15079763
OBJECTIVES: To evaluate the efficacy and safety of interferon (IFN) alpha for the treatment of Behçet's disease (BD) and discuss its possible mechanisms of action. ...The indexing terms used were "Behçet" and "interferon." RESULTS: Thirty-two original reports and 4 selected abstracts were included in the analysis. ...
OBJECTIVES: To evaluate the efficacy and safety of interferon (IFN) alpha for the treatment of Behçet's disease (BD) and discuss its …
Novel treatment strategies for myeloproliferative neoplasms
Bose P, et al. Rinsho Ketsueki 2019 - Review. PMID 31597841
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromosome negative (Ph(-)) myeloproliferative neoplasms, years of drug development efforts have begun to bear fruit with the recent approval of a novel monopegylated interferon alfa-2b, ropeginterferon alfa, for patients with polycythemia vera without symptomatic splenomegaly in Europe. ...
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromos …
[THERAPEUTIC POTENTIAL OF ALPHA-INTERFERON PREPARATIONS DUR- ING SOCIALLY-SIGNIFICANT HUMAN DISEASES OF VIRAL ETIOLOGY].
Ospelnikova TP, et al. Zh Mikrobiol Epidemiol Immunobiol 2016 - Review. PMID 30695356 Russian.
Interferons (IFN) belong to key cytokines of innate and adaptive immune response and play an important role in anti-viral and anti-tumor protection. ...
Interferons (IFN) belong to key cytokines of innate and adaptive immune response and play an important role in anti-viral and anti-tu
Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J. Vnitr Lek 2019. PMID 31906676
Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its widespread use has been limited by higher frequency of short-term adverse reactions compared to conventional treatment and until recently, by its off-label indication in BCR/ABL negative MPNs. ...
Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its wid
[Alpha interferon induced hyperthyroidism: a case report and review of the literature].
Maiga I, et al. Rev Med Liege 2015 - Review. PMID 26376567 French. Free article.
Factors predicting thyroid dysfunction with interferon use are: female sex, history of thyroid disease and previous autoimmunity. ...Antithyroid drugs radioactive iodine or thyroid surgery are used in cases of severe or persistent Graves' disease induced by alpha interferon....
Factors predicting thyroid dysfunction with interferon use are: female sex, history of thyroid disease and previous autoimmunity. ... …
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera.
Foa P, et al. Eur J Haematol 1998. PMID 9654155
We report on long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a (rIFN-alpha) in a series of 38 patients with polycythaemia vera (PV). ...
We report on long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a (rIFN-alpha) in a series of 38 patients w …
Therapeutic alpha-interferons protein: structure, production, and biosimilar.
El-Baky NA and Redwan EM. Prep Biochem Biotechnol 2015 - Review. PMID 24785737
There are three major classes of interferons in humans: IFN-alpha, IFN-beta, and IFN-gamma. As a treatment option, interferon-alpha (IFN-α) is the most effective one. ...Recently, novel pegylated IFN-α2 products with extended in vivo half-lives and consensus interferon, an artificially engineered type I interferon, have been developed to substantially improve treatment regimes for HCV patients. ...
There are three major classes of interferons in humans: IFN-alpha, IFN-beta, and IFN-gamma. As a treatment option, interferon- …
Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.
Dec M and Puchalski A. Pol J Vet Sci 2008 - Review. PMID 18683548
Interferon-alpha (IFN-alpha) is well known as a clinically effective antiviral and antineoplastic therapeutic agent. It has also been shown to have immunoregulatory properties. ...Moreover, the injectable high-dose interferon therapy currently approved for various human disorders causes numerous side effects. ...
Interferon-alpha (IFN-alpha) is well known as a clinically effective antiviral and antineoplastic therapeutic agent. It has also been
Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?
Sabel MS and Sondak VK. Drugs 2003 - Review. PMID 12749732
On the basis of these results, the US FDA approved high-dose interferon-alpha-2b for the post-surgical adjuvant therapy of high-risk melanoma. ...This article reviews the existing data and attempt to address the arguments for and against a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma....
On the basis of these results, the US FDA approved high-dose interferon-alpha-2b for the post-surgical adjuvant therapy of high-risk …
20,238 results
Jump to page
Feedback